Discovery of New Tuberculosis Drug Leads Targeting Cell Wall Biosynthesis

发现针对细胞壁生物合成的新结核病药物先导物

• 批准号: nhmrc : GNT1082533
• 负责人: Dr Nicholas West
• 金额: $ 46.16万
• 依托单位: University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/discovery-new-tuberculosis-wall-biosynthesis/1345466
• 关键词: Discovery; New; Tuberculosis; Drug; Leads

There is a desperate need for the development of new therapies for the treatment of TB due to widespread resistance of Mycobacterium tuberculosis, the causative agent of TB, to current therapies. The overall goal of this research project is to identify new TB drug leads through the development of structural analogues of bacterially-derived natural products called the sansanmycins that inhibit cell wall synthesis in Mycobacterium tuberculosis.

由于结核分枝杆菌（TB的病原体）对当前疗法的广泛抗性，迫切需要开发用于治疗TB的新疗法。该研究项目的总体目标是通过开发细菌衍生的天然产物（称为sansanmycins）的结构类似物来确定新的结核病药物，这些天然产物可抑制结核分枝杆菌的细胞壁合成。